Thermo Fisher Scientific Inc., the world leader in serving science, today announced a co-marketing agreement with Biognosys AG, leader in next-generation proteomics, to provide a comprehensive, efficient workflow to enable library creation and data processing for Data-Independent Acquisition (DIA) studies, through the combined use of Orbitrap mass spectrometers and Spectronaut Pulsar software.
Compatible with the new Thermo Scientific Q Exactive HF-X Hybrid Quadrupole Orbitrap mass spectrometer, in addition to previous Orbitrap instruments, the Biognosys Spectronaut Pulsar software allows researchers to conduct data-independent analysis using MS1 quantitation for reproducible and accurate quantitation of thousands of proteins in a single run. DIA is a global method for the comprehensive recording of spectral signatures from all components of a sample, and can be used in combination with the latest high-resolution Orbitrap instruments as a universal method for global expression profiling.
“DIA is part of our quantitative proteomics arsenal. It is it an excellent fit for discovery proteomics, providing both high depth of proteome coverage in large sample series and the ability to reproduce data points more precisely between technical replicates than other methods. As such, it complements other quantitative techniques such as Tandem Mass Tags (TMT) and Parallel Reaction Monitoring (PRM),” said Andreas Huhmer, director, proteomics and metabolomics marketing, chromatography and mass spectrometry, Thermo Fisher. “The Spectronaut Pulsar software creates an efficient pipeline for spectral library creation and processing of large DIA datasets.”
“We developed Spectronaut Pulsar to support our own contract DIA services business, as well as our research customers with access to high-resolution instruments,” said Lukas Reiter, chief technology officer, Biognosys. “It has been extensively optimized to take advantage of HRAM data from Orbitrap mass spectrometers as this is the platform we work on ourselves. Spectronaut Pulsar is easy to use, very fast and able to process very large datasets and every detail was optimized to provide the best possible quantitative results.”
Orbitrap mass spectrometry, which was introduced by Thermo Fisher more than 10 years ago, is well accepted as the gold standard platform for proteomics research. As part of the collaboration, both companies will continue to further build upon and optimize DIA-related workflows.
Thermo Fisher is featuring the software and instruments during the 65th Annual American Society for Mass Spectrometry (ASMS) Conference, being held June 4-8, in the White River Ballroom F-J at the JW Marriott, Indianapolis. For more information on Thermo Fisher’s proteomics solutions, visit thermofisher.com/asms.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of $18 billion and more than 55,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more information, please visit www.thermofisher.com.
About Biognosys
Biognosys is the leading proteomics company offering innovative services and products for highly multiplexed protein quantification. We are dedicated to transforming the life sciences with superior proteomics solutions. Biognosys’ next generation technology quantifies proteins with unbeatable precision and depth. Our solution relies on mass spectrometry, which allows simultaneous quantification of thousands of proteins in a single experiment. This new generation protein quantification technology is available to researchers worldwide through our contract research services or our portfolio of innovative reagent and software products. For more information, please visit www.biognosys.com.
###